Search Results

Archived - Important safety information regarding Serevent® in Asthma (salmeterol xinafoate) and cessation of the SMART (Salmeterol Multi-center Asthma Research Trial) - GlaxoSmithKline Inc.

Archived - Important Safety Information Regarding The Discontinuation Of Sales - Linnefazodone In Canada: Letter To Pharmacists And Wholesalers

Archived - Important safety information on the concomitant use of GlucoNorm® (repaglinide) and gemfibrozil. - Novo Nordisk Canada Inc.

Suspension of marketing of Raptiva (efalizumab) in Canada - For Health Professionals

Archived - Suspension of marketing of Raptiva (efalizumab) in Canada - For the Public

Archived - New Safety Information Regarding Progressive Multifocal Leukoencephalopathy (PML) Associated with TYSABRI (natalizumab) - For the Public

New Safety Information Regarding Progressive Multifocal Leukoencephalopathy (PML) Associated with Tysabri (natalizumab) - For Health Professionals

Important safety information on pms-Sodium Phosphates Oral Solution with kidney impairment and nephrocalcinosis - For Health Professionals - Pharmascience Inc.

Lip Gloss Keychains Recalled By Markwins Beauty Products Due to Risk of Lead Exposure

The metal clasp attached to the keychain contains high levels of lead. Lead is toxic if ingested by young children and can cause adverse health effects.

Additional safety information related to Botox and Botox Cosmetic (botulinum toxin type A) - For Health Professionals

Archived – New Safety Information Regarding Botox and Botox Cosmetic Products

Recall of certain lots of Dobutamine Hydrochloride Injection 250 mg /20 ml due to labelling error regarding dose - For Health Professionals

Archived - Important Changes to the Dosage Guidelines for Fentanyl Transdermal Systems (Patches) - For the Public

Important Changes to the Dose Conversion Guidelines for Fentanyl Transdermal Systems - Notice to Hospitals

Important Changes to the Dose Conversion Guidelines for Fentanyl Transdermal Systems - For Health Professionals

Recall of Lot 7101490 of PPC Piperacillin/Tazobactam for Injection, 4.5g/vial - For Health Professionals

Association of Raptiva (efalizumab) with serious infections, including progressive multifocal leukoencephalopathy in patients with psoriasis - For Health Professionals

Archived - Association of Raptiva (efalizumab) with serious infections, including progressive multifocal leukoencephalopathy in patients with psoriasis - For the Public

Reports of Eye Inflammation, Endophthalmitis, and Toxic Anterior Segment Syndrome (TASS) Following Off-label Intravitreal Use of Avastin (bevacizumab) - For Health Professionals

Archived - Reports of Eye Inflammation, Endophthalmitis, and Toxic Anterior Segment Syndrome (TASS) Following Off-label Intravitreal Use of Avastin (bevacizumab) - For the Public

Archived – Health Canada Releases Decision on the Labelling of Cough and Cold Products for Children

New safety information

Archived - The use of Tarceva (erlotinib) in patients with moderate hepatic impairment and advanced solid tumours - For the Public

The use of Tarceva (erlotinib) in patients with moderate hepatic impairment and advanced solid tumours - For Health Professionals

Possible interference of icodextrin, intravenous immunoglobulins, galactose and d-xylose with certain blood glucose meters - Notice to Hospitals